Cargando…
Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis
PURPOSE: To report the first patient with ocular toxoplasmosis treated with a slow-release biodegradable intravitreal clindamycin implant. OBSERVATIONS: A 39-year-old human immunodeficiency virus (HIV)-positive woman with recurrent toxoplasmic retinochoroiditis and vitritis for whom oral medication...
Autores principales: | Jorge, Rodrigo, Coelho, Igor Neves, Silva-Cunha, Armando, Fernandes Cunha, Gabriella Maria, Scott, Ingrid U., Fialho, Silvia Ligório, Furtado, João Marcello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085661/ https://www.ncbi.nlm.nih.gov/pubmed/33981913 http://dx.doi.org/10.1016/j.ajoc.2021.101093 |
Ejemplares similares
-
Clinical outcomes of intravitreal treatment for ocular toxoplasmosis: systematic review and meta-analysis
por: de Melo, Lutiana Amaral, et al.
Publicado: (2023) -
Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
por: Shah, Nikunj J, et al.
Publicado: (2011) -
Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
por: Pandey, Neeraj, et al.
Publicado: (2013) -
Neuroprotective Effect of siRNA Entrapped in Hyaluronic Acid-Coated Lipoplexes by Intravitreal Administration
por: Ribeiro, Marcela Coelho Silva, et al.
Publicado: (2021) -
Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation
por: Lage, Nayara Almeida, et al.
Publicado: (2023)